GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » Asset Turnover

Intec Parent (Intec Parent) Asset Turnover : 0.00 (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Intec Parent Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Intec Parent's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Intec Parent's Total Assets for the quarter that ended in Mar. 2021 was $19.16 Mil. Therefore, Intec Parent's Asset Turnover for the quarter that ended in Mar. 2021 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Intec Parent's annualized ROE % for the quarter that ended in Mar. 2021 was -130.74%. It is also linked to ROA % through Du Pont Formula. Intec Parent's annualized ROA % for the quarter that ended in Mar. 2021 was -88.27%.


Intec Parent Asset Turnover Historical Data

The historical data trend for Intec Parent's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Asset Turnover Chart

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Asset Turnover
Get a 7-Day Free Trial - - - - -

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intec Parent's Asset Turnover

For the Biotechnology subindustry, Intec Parent's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Parent's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Parent's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Intec Parent's Asset Turnover falls into.



Intec Parent Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Intec Parent's Asset Turnover for the fiscal year that ended in Dec. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2020 )/( (Total Assets (A: Dec. 2019 )+Total Assets (A: Dec. 2020 ))/ count )
=0/( (21.28+20.896)/ 2 )
=0/21.088
=0.00

Intec Parent's Asset Turnover for the quarter that ended in Mar. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2021 )/( (Total Assets (Q: Dec. 2020 )+Total Assets (Q: Mar. 2021 ))/ count )
=0/( (20.896+17.43)/ 2 )
=0/19.163
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Intec Parent  (NAS:NTEC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Intec Parent's annulized ROE % for the quarter that ended in Mar. 2021 is

ROE %**(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-16.916/12.9385
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-16.916 / 0)*(0 / 19.163)*(19.163/ 12.9385)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.4811
=ROA %*Equity Multiplier
=-88.27 %*1.4811
=-130.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Intec Parent's annulized ROA % for the quarter that ended in Mar. 2021 is

ROA %(Q: Mar. 2021 )
=Net Income/Total Assets
=-16.916/19.163
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-16.916 / 0)*(0 / 19.163)
=Net Margin %*Asset Turnover
= %*0
=-88.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Intec Parent Asset Turnover Related Terms

Thank you for viewing the detailed overview of Intec Parent's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent (Intec Parent) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco director 7 HAORANIM STREET BAZRA L3 60944